ECSP078063A - Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación - Google Patents

Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación

Info

Publication number
ECSP078063A
ECSP078063A EC2007008063A ECSP078063A ECSP078063A EC SP078063 A ECSP078063 A EC SP078063A EC 2007008063 A EC2007008063 A EC 2007008063A EC SP078063 A ECSP078063 A EC SP078063A EC SP078063 A ECSP078063 A EC SP078063A
Authority
EC
Ecuador
Prior art keywords
amino
methyl
chinolinocarbonitrile
metoxifenil
propoxi
Prior art date
Application number
EC2007008063A
Other languages
English (en)
Inventor
Henry Lee Strong
Marc S Tesconi
Hong Wen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP078063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP078063A publication Critical patent/ECSP078063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se dirige a un monohidrato cristalino de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo que tiene un patrón de difracción de rayos X en donde los ángulos 2? (º) de picos significativos están en aproximadamente: 9.19, 11.48, 14.32, 19.16, 19.45, 20,46, 21.29, 22.23, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61 y 29.51, y una temperatura de transición de aproximadamente 109º C a aproximadamente 115º C.
EC2007008063A 2005-07-01 2007-12-28 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación ECSP078063A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
ECSP078063A true ECSP078063A (es) 2008-01-23

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008063A ECSP078063A (es) 2005-07-01 2007-12-28 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación

Country Status (24)

Country Link
US (2) US7767678B2 (es)
EP (1) EP1902029B2 (es)
JP (1) JP2009500332A (es)
KR (1) KR20080028386A (es)
CN (1) CN101248047A (es)
AR (1) AR054505A1 (es)
AU (1) AU2006266045A1 (es)
BR (1) BRPI0613574A2 (es)
CA (1) CA2613053C (es)
CR (1) CR9596A (es)
DK (1) DK1902029T4 (es)
EC (1) ECSP078063A (es)
ES (1) ES2449197T5 (es)
GT (1) GT200600282A (es)
IL (1) IL188483A0 (es)
MX (1) MX2008000384A (es)
NO (1) NO20080051L (es)
PA (1) PA8685101A1 (es)
PE (1) PE20070190A1 (es)
PL (1) PL1902029T5 (es)
PT (1) PT1902029E (es)
RU (1) RU2007148072A (es)
TW (1) TW200740797A (es)
WO (1) WO2007005462A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766067A1 (en) * 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
JP2007502819A (ja) * 2003-08-19 2007-02-15 ワイス・ホールディングズ・コーポレイション ４−アミノ−３−キノリンカルボニトリルの調製方法
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
CA2610209A1 (en) * 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
ES2449197T5 (es) 2022-04-28
ES2449197T3 (es) 2014-03-18
AR054505A1 (es) 2007-06-27
KR20080028386A (ko) 2008-03-31
PT1902029E (pt) 2014-03-05
HK1114614A1 (en) 2008-11-07
TW200740797A (en) 2007-11-01
CN101248047A (zh) 2008-08-20
PA8685101A1 (es) 2007-01-17
DK1902029T4 (da) 2022-02-28
CR9596A (es) 2008-03-06
WO2007005462A1 (en) 2007-01-11
EP1902029A1 (en) 2008-03-26
NO20080051L (no) 2008-01-29
JP2009500332A (ja) 2009-01-08
IL188483A0 (en) 2008-04-13
EP1902029B1 (en) 2014-01-08
PL1902029T3 (pl) 2014-08-29
PE20070190A1 (es) 2007-03-20
US20070015767A1 (en) 2007-01-18
BRPI0613574A2 (pt) 2016-11-16
RU2007148072A (ru) 2009-08-10
MX2008000384A (es) 2008-03-07
US8445496B2 (en) 2013-05-21
US7767678B2 (en) 2010-08-03
AU2006266045A1 (en) 2007-01-11
EP1902029B2 (en) 2022-02-16
CA2613053A1 (en) 2007-01-11
PL1902029T5 (pl) 2022-08-29
GT200600282A (es) 2007-02-14
CA2613053C (en) 2015-11-24
DK1902029T3 (en) 2014-02-17
US20100324066A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
ECSP078063A (es) Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación
DK1940786T3 (da) Biphenylderivater og deres anvendelse ved behandling af hepatitis C
DK2332909T3 (da) Hydroxybenzamidderivater og deres anvendelse som inhibitorer af hsp90
NO20081685L (no) Fremgangsmate for fremstilling oksazolidin-beskyttelse aminodolforbindelser anvendbare som mellomprodukter for Florfenicol
BRPI0615029A2 (pt) processos e intermediários
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
EA200800865A1 (ru) Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
BRPI0516905A (pt) processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos
EA200702586A1 (ru) Кристаллические модификации пираклостробина
EP1773846A4 (en) INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
BRPI0710199A2 (pt) Processo para preparação de inibidores de hiv protease
ECSP066721A (es) Inhibidores novedosos de quimasa
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
ITMI20021391A1 (it) Nitroderivati di inibitori della cicloossigenasi-2
BRPI0515470A (pt) processos e intermediários para preparação de inibidores de cisteìna protease
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
BRPI0715051A2 (pt) Processo e intermediários para a síntese de derivados de 2-(quinolin-5il)-4,5 dissubstituído-azol
AR052681A1 (es) Formas cristalinas de 2-(3-fluoro-4 hidroxifenil ) -7 -vinil-1,3- benzoxazol -5-ol
EA200801109A1 (ru) Состав для литья и способ его получения
EP1997802A4 (en) METHOD FOR NITRATING ISOUREA
CR9327A (es) Procedimiento para la preparacion de compuestos benzoxazol sustituidos
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
AR058755A1 (es) Formas polimorfas cristalinas de clorhidrato de olopatadina y procesos para su preparacion
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина